logo
Reetha vs Rosemary: Which is better for quick hair growth?

Reetha vs Rosemary: Which is better for quick hair growth?

Time of India3 days ago
Reetha and rosemary, age-old hair care secrets, offer distinct benefits. Reetha cleanses and strengthens the scalp, creating a healthy environment for growth. Rosemary stimulates follicles, boosting circulation and promoting faster hair growth. While reetha requires more preparation, rosemary is easier to use. Combining both can provide a powerful, natural approach to achieving longer, stronger hair.
When it comes to hair growth, we'll try just about anything. Onion juice? Been there. Rice water? Tried that. But two ingredients that have been in the hair care spotlight (and in our grandma's beauty secrets) are Reetha and Rosemary.
Both are totally natural, have their own loyal fan clubs, and claim to give you longer, stronger hair.
But if you're in a hurry to grow your hair out - like, yesterday which one actually works better?
Let's break it down.
First up, what's Reetha?
Reetha, or soapnut, has been a go-to in Indian households for ages. It's basically nature's OG shampoo. When soaked and boiled, it lathers up like soap, minus all the chemicals. But it's not just a cleanser, it does way more than that.
Reetha can:
Deep clean your scalp
Help reduce dandruff
Strengthen your roots
Add softness and shine
If your scalp is full of product buildup, gunk, or oil, Reetha gets it all out without stripping your hair dry. And let's be honest, a clean scalp is the first step to growing healthy hair.
Now meet Rosemary, YouTube's favourite hair growth hero
Rosemary is the herb that's suddenly everywhere, especially in the form of rosemary oil. And there's actually science behind the hype.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Is this legal? Access all TV channels without a subscription!
Techno Mag
Learn More
Undo
Studies show it can work just as well as minoxidil (yep, the stuff in hair regrowth treatments).
Rosemary is great for:
Boosting blood circulation in the scalp
Reawakening sleepy hair follicles
Reducing hair fall
Thickening your strands over time
If your hairline's thinning or you're noticing bald patches, rosemary might just be the hero you need.
How do they actually help with hair growth?
Reetha works by creating the perfect environment.
It doesn't directly grow hair super fast, but it gives your scalp a serious detox.
It removes dandruff, buildup, and excess oil, which can clog your follicles and slow down growth. Think of it as prepping the soil before planting.
Rosemary, on the other hand, is a follicle stimulator.
It helps bring more oxygen and nutrients to your roots, which encourages new hair to grow faster and stronger. If your goal is to speed things up and see baby hairs popping, rosemary is the one.
Ease of use? Let's talk convenience.
Reetha takes a little effort.
You need to soak it, boil it, and make a DIY hair cleanser. Or, you can buy Reetha-based shampoos, but most people still swear by the homemade version. It's effective, but kind of messy.
Rosemary is super easy. Just mix rosemary oil with a carrier oil (like coconut or almond), massage it into your scalp, leave it on for a few hours or overnight, and wash it out. You can even make a rosemary water rinse by boiling a few sprigs in water and using that after shampooing.
So if you're all about low-effort routines, rosemary wins this round.
Any side effects to worry about?
Both are pretty safe if used right, but a few things to note:
Reetha can dry your hair out if you use it too often or don't follow up with conditioner or oil.
Rosemary oil is strong stuff, never apply it straight to your scalp. Always dilute it first, or you could end up with a tingly, irritated scalp.
Pro tip: Always do a patch test before trying anything new, natural or not.
So, who's the winner for quick hair growth?
Here's the deal:
If you want to cleanse and strengthen your scalp and keep things super natural, Reetha is your girl.
But if you're looking to boost growth faster and actually see results sooner, Rosemary has the edge.
That said, why not use both?
Start by washing your hair with a gentle Reetha cleanser once or twice a week, then massage in rosemary oil before bed a few times a week. Together, they make a pretty powerful hair growth team.
There's no overnight miracle for Rapunzel hair, but with consistency (and a little patience), both Reetha and Rosemary can give you amazing results. If you want quicker growth, rosemary is the one to lean on. If you want a super healthy scalp, Reetha's your best friend.
Honestly, your hair deserves the best of both worlds.
So, go ahead brew that Reetha, oil up with Rosemary, and let your hair do the talking.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

World Hepatitis Day: Early symptoms and spread of Hepatitis B
World Hepatitis Day: Early symptoms and spread of Hepatitis B

Time of India

time33 minutes ago

  • Time of India

World Hepatitis Day: Early symptoms and spread of Hepatitis B

World Hepatitis Day is observed each year on 28 July to raise awareness of viral hepatitis, an inflammation of the liver that causes severe liver disease and liver cancer. This year's theme is Hepatitis: Let's Break It Down, shows urgency, a prompt action to dismantle the financial, social stigma that is attached to this condition against eliminating it. According to data published by the World Health Organisation (WHO) 304 million people are living with chronic hepatitis B and C since 2022, and 1.3 million people died of it in 2022 itself. Dr. Catharia Beohme, officer-in-charge of the WHO South-east Asia region, clearly stated that Viral hepatitis continues to be a needless suffering among thousands of innocent people, silently attacking our liver, spreading cancer, and causing hundreds of thousands of preventable deaths each year. She said, 'Across the Region, an estimated 61 million people live with hepatitis B, and 9 million with hepatitis C. Our Region bears one of the highest burdens of chronic viral hepatitis globally, yet most people living with the disease remain undiagnosed and untreated.' this is a global burden we are all suffering under and this needs to be addressed as son as possible. According world hepatitis alliance, Hepatitis is the world's deadliest virus after COVID-19, and more than 300 million people are living with hepatitis. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Susan Boyle Is Now so Thin and Looks Beautiful! Undo Surprisingly, it is the leading cause of liver cancer. What is Hepatitis Hepatitis is an inflammatory disease of the liver that is caused by infectious viruses and Noninfectious agents, leading to a range of health problems, including severe liver damage and cancer, which we all know how deadly it is. There are 5 major strains of this virus,s namely A, B, C,D and E. While the other is no less than the first, particularly, each of them offer a different kind of liver disease. In particular, types B and C lead to chronic disease in hundreds of millions of people and together are the most common cause of liver cirrhosis, liver cancer and viral hepatitis-related deaths. What are the symptoms of Hepatitis People with hepatitis may or may not exhibit symptoms. Major symptoms include: Fever Malaise Loss of appetite Nausea Diarrhoea Abdominal discomfort Jaundice Dark-coloured urine Specifically, hepatitis B, C, and D can cause liver infection, which can later develop in liver cirrhosis or liver cancer. How to protect ourselves against Hepatitis B and its spread Hepatitis B is an infection of the liver caused by the hepatitis B virus. The infection can be acute (short and severe) or chronic (long term). Hepatitis B can be prevented with a safe and effective vaccine. The vaccine is usually given soon after birth with boosters a few weeks later. It offers nearly 100% protection against the virus. Ways it can be contracted Hepatitis B can commonly spread from mother to her child at birth or through horizontal transmission, especially from an infected child to an uninfected child during the first 5 years of their life. Hepatitis B is also spread by an infected person's needle, tattooing, piercing and exposure to infected blood and body fluids, such as saliva and menstrual, vaginal, and seminal fluids. Transmission of the virus may also occur through the sharing or reuse of contaminated needles and syringes or sharp objects, either in health care settings, in the community or among persons who inject drugs. Sexual transmission is more prevalent in unvaccinated persons with multiple sexual partners. Is it easily diagnosed? Its diagnosis requires a lab test, as its symptoms can mimic other hepatitis symptoms as well. WHO recommends screening in high-prevalence areas, pregnant women, blood donors, and high-risk groups. Only 13% of infected people knew their status in 2022, and 3% were receiving treatment. Coinfection with HIV occurs in about 1% of Hepatitis B cases; treatment for HIV often also treats Hepatitis B (WHO) Hepatitis, especially Hepatitis B remains a significant global health challenge, affecting millions, to reduce this global burden, this is an earnest request to spread as much information about it as possible, as this deadly disease requires a coordinated global action.

New IPO: NephroPlus files papers with Sebi for ₹353.4 crore IPO to expand Dialysis clinics
New IPO: NephroPlus files papers with Sebi for ₹353.4 crore IPO to expand Dialysis clinics

Mint

timean hour ago

  • Mint

New IPO: NephroPlus files papers with Sebi for ₹353.4 crore IPO to expand Dialysis clinics

Nephrocare Health Services Limited, widely recognized under the brand name NephroPlus, has filed a Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) to raise ₹353.4 crore through an initial public offering (IPO). The Hyderabad-based company plans to use the proceeds to expand its network of dialysis clinics across India and repay outstanding debt, with the balance allocated to general corporate purposes. Advertisement The IPO will include a fresh issue of equity shares worth ₹353.4 crore and an offer-for-sale (OFS) of up to 1.27 crore equity shares by promoter and non-promoter shareholders. Among the OFS participants are Investcorp Private Equity Fund II, Healthcare Parent Limited, Edoras Investment Holdings Pte. Ltd., and 360 One Special Opportunities Fund. The company may also consider a pre-IPO placement of up to ₹70.6 crore, which would reduce the size of the fresh issue accordingly. Asia's Largest Dialysis Service Provider Established in 2009, NephroPlus has emerged as Asia's largest dialysis services provider and the fifth-largest globally in terms of the number of treatments performed in FY25, according to a Frost & Sullivan report. As of now, the company operates 447 clinics across 269 cities in 21 Indian states and 4 Union Territories, serving over 33,000 patients annually. NephroPlus commands more than 50 percent revenue market share in India's organised dialysis services market. Advertisement NephroPlus has also made a significant push into international markets. It currently operates 34 clinics in the Philippines, 5 in Nepal, 4 in Uzbekistan, and recently entered Saudi Arabia in a bid to tap the Middle East healthcare market. The company's promoters include Vikram Vuppala, BVP Trust (Bessemer Venture Partners), and Investcorp-affiliated entities. Proceeds to Fuel Domestic Expansion As per the DRHP, NephroPlus will allocate ₹129.1 crore from the fresh issue proceeds towards setting up new dialysis clinics in India, which aligns with its strategy to grow its domestic footprint. An additional ₹136 crore will be used to pre-pay or repay certain existing borrowings, enhancing the company's financial flexibility and improving its balance sheet. Advertisement In FY25, the company reported ₹755.8 crore in revenue from operations and a profit after tax of ₹67 crore, reflecting robust growth amid increasing demand for kidney care services. With chronic kidney disease (CKD) rising as the third fastest-growing cause of death globally, and diabetes and hypertension being its primary drivers, NephroPlus is well-positioned to benefit from secular health trends. ICICI Securities, Ambit Private Limited, IIFL Capital Services, and Nomura Financial Advisory and Securities (India) are acting as Book Running Lead Managers (BRLMs) for the IPO. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions. Advertisement

'World-class care, at home': Kuwait seals landmark collaboration with five elite French hospitals in Paris
'World-class care, at home': Kuwait seals landmark collaboration with five elite French hospitals in Paris

Time of India

timean hour ago

  • Time of India

'World-class care, at home': Kuwait seals landmark collaboration with five elite French hospitals in Paris

TL;DR: Kuwait 's Minister of Health, Dr Ahmad Al‑Awadhi, signed memoranda of understanding on July 18, 2025 with five elite French medical institutions. Participating organizations: Almaviva Santé, Institut Curie , Hôpital Foch, Institut Mutualiste Montsouris , and Rothschild Foundation Hospital. The MoUs enable specialist consultations, telemedicine, international fellowships, on-shore training, and joint clinical research in key areas: oncology, cardiology, organ transplantation, and diagnostics. Patient benefits include access to world-class expertise without overseas travel; health professionals gain advanced training through international exchange programs. On July 18, 2025, Kuwait's Minister of Health, Dr Ahmad Al‑Awadhi, formalized a series of strategic memoranda of understanding with five premier French medical institutions during a ceremony in Paris as reported by KUNA. Tired of too many ads? go ad free now The move marks a new chapter in Kuwait's healthcare collaboration with France, aimed at advancing medical expertise, expanding training opportunities for Kuwaiti professionals, and enhancing patient access to world‑class care through remote and local channels. The agreements were executed in alignment with Kuwait's leadership vision, as expressed by Amir Sheikh Meshal Al‑Ahmad Al‑Jaber Al‑Sabah. A Strategic Vision Rooted in National Development The MoUs reflect a broader vision championed byAmir Sheikh Meshal Al-Ahmad Al-Jaber Al-Sabah, emphasizing international partnerships to uplift Kuwait's healthcare quality and self-reliance. According to Dr Al-Awadhi, this move represents a 'new beginning' in bilateral cooperation that will not only strengthen patient care infrastructure but also position Kuwait as a regional hub for specialized medical services. By aligning Kuwait's healthcare goals with the expertise of global leaders in medicine, the Ministry aims to expand local treatment capabilities, particularly in oncology, cardiology, organ transplantation, and complex diagnostics—while also improving knowledge exchange mechanisms through fellowships and dual training programs. Top-Tier French Institutions on Board The five French entities involved include: Almaviva Santé: a leading private hospital group across France, known for surgical excellence. Institut Curie: globally recognized for cutting-edge oncological research and treatment. Hôpital Foch: a pioneer in organ transplantation and thoracic surgery. Institut Mutualiste Montsouris: acclaimed for high-precision cardiology and urology services. Rothschild Foundation Hospital: a Paris-based reference center in neurology and ophthalmology. Each institution brings decades of proven expertise and world-class infrastructure to the collaboration. These partnerships aim to offer Kuwaiti patients specialist tele-consultations, expert second opinions, and remote care options, all within Kuwait's borders, reducing travel costs and patient fatigue. What the Agreements Cover: From Training to Telemedicine The MoUs are multifaceted in scope and tailored to address both clinical and capacity-building needs in Kuwait's healthcare ecosystem. Among the key pillars: Specialist Telemedicine Services French physicians will provide virtual consultations for complex cases, enhancing diagnostic accuracy and offering patients access to second opinions from leading European experts. Tired of too many ads? go ad free now This reduces Kuwait's reliance on outbound medical travel while maintaining high standards of care. Physician Training & Clinical Fellowships Healthcare professionals from Kuwait will benefit from structured training programs, including short-term fellowships, clinical observerships, on-site placements in France, and joint workshops in Kuwait. This hands-on learning model is expected to upskill frontline medical staff, particularly in areas where Kuwait lacks in-house specialization. On-Site Diagnostics Support The French institutions will send diagnostic experts to Kuwait on rotational visits to conduct complex medical tests, improve lab capabilities, and support local clinicians with advanced case management. Focus areas include oncopathology, cardiac imaging, and genetic testing. Joint Research & Innovation Both sides have committed to launching clinical trials and collaborative research projects, particularly targeting diseases prevalent in the Gulf region such as diabetes, hypertension, and cancer. The aim is to co-develop innovative treatment protocols that could later be scaled for regional application. Why This Matters to Kuwait's Healthcare Future These MoUs go beyond symbolic cooperation, they signify a functional model for technology-driven, collaborative healthcare that integrates global expertise with local needs. By leveraging France's longstanding medical legacy, Kuwait hopes to: Reduce medical travel costs and improve in-country care Develop specialist medical talent through international mentorship Advance diagnostic infrastructure and patient outcomes Promote research culture and knowledge production within national institutions The Ministry of Health views these collaborations as a strategic investment in both human capital and system resilience. Kuwait's new healthcare agreements with elite French hospitals are a calculated step toward building a globally competitive medical ecosystem. As implementation begins, the MoUs are expected to deliver both immediate benefits to patients and long-term advantages for professional development. With stronger institutional ties and shared scientific goals, Kuwait is not only addressing present-day healthcare gaps but also future-proofing its medical services for generations to come. FAQ 1. What are the new healthcare MoUs Kuwait signed with France? Kuwait signed memoranda of understanding with five top French medical institutions to enhance diagnostics, treatment, training, and research. 2. Which French hospitals are involved in the agreements? The MoUs involve Almaviva Santé, Institut Curie, Hôpital Foch, Institut Mutualiste Montsouris, and Rothschild Foundation Hospital. 3. Will Kuwaiti patients be sent to France for treatment? While some critical cases may still go abroad, the focus is on bringing French expertise to Kuwait and expanding local services. 4. How will Kuwaiti doctors benefit from this deal? Doctors will receive training, attend fellowships in France, and collaborate on research and clinical programs with French specialists. 5. When will these agreements take effect? The agreements were signed in July 2025 and are expected to be rolled out in phases starting later this year.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store